Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Two new studies have been published that further focus attention on how the renin–angiotensin ...
The renin-angiotensin system (RAS) remains a cornerstone of cardiovascular and renal physiology, orchestrating vital aspects of blood pressure regulation and fluid-electrolyte balance. At the heart of ...
The renin-angiotensin system (RAS) becomes active at low blood pressure and forms angiotensin II, a hormone that causes blood vessels to constrict, causing blood pressure to rise again. The enzyme ...
As the COVID-19 pandemic drags on, scientists worldwide are racing to understand how the virus affects the body. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 ...
Profs Ravi Acharya and Edward Sturrock review the historical foundation, present landscape and future clinical promise of ACE inhibition.
Please provide your email address to receive an email when new articles are posted on . After a hyperkalemia event, mineralocorticoid receptor antagonists were discontinued in up to 46% of patients.
a Multivariate model adjusting for cancer therapy including antimetabolites, Vascular endothelial growth factors inhibitors, taxanes, tyrosine kinase inhibitors, monoclonal antibodies, vinca alkaloids ...
Studies in animals have shown that ACE2 is used by coronaviruses as a functional receptor. ARBs and ACE inhibitors increase the expression of ACE2; a hypothesis that their use may modify ...
Investigators are assessing whether treatment with the angiotensinogen-targeting RNAi agent reduces patients' risk of cardiovascular disease.
Many patients with T2D and incident cardiovascular comorbidities do not adhere to guideline-recommended care and have worse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback